Fluorescent Imaging Demystifies Melanoma
Study validates non-invasive molecular imaging device for point-of-care assessment of suspicious moles
-
By
-
Helen Bristow
-
February 10, 2026
-
Clinical Scorecard: Fluorescent Imaging Demystifies Melanoma
At a Glance
| Category | Detail |
|---|
| Condition | Melanoma |
| Key Mechanisms | In vivo molecular imaging to identify biological tissue remodeling associated with melanoma development. |
| Target Population | Patients with atypical or difficult-to-characterize pigmented lesions. |
| Care Setting | Dermatology clinics using point-of-care testing. |
Key Highlights
- SFI system shows 100% detection of oncogenic activity in melanoma cases.
- AUC of 0.907 indicates solid discriminatory performance for lesion triage.
- SFI provides molecular information that complements visual assessment.
- Potential to reduce unnecessary biopsies and identify aggressive cancers early.
- Higher sensitivity and specificity compared to traditional dermoscopy.
Guideline-Based Recommendations
Diagnosis
- Utilize SFI for non-invasive assessment of atypical pigmented lesions.
Management
- Biopsy lesions with high SFI scores indicating high likelihood of melanoma.
Monitoring & Follow-up
- Monitor lesions without evidence of tissue remodeling activity.
Risks
- Risk of misclassification of lesions without SFI assessment.
Patient & Prescribing Data
Individuals with atypical pigmented lesions.
SFI can guide treatment decisions based on molecular activity.
Clinical Best Practices
- Incorporate SFI alongside ABCDE criteria for lesion evaluation.
- Use SFI to inform biopsy decisions and reduce unnecessary procedures.
- Consider SFI results in conjunction with patient history and visual assessments.
References
